Hetta Gouse1, John A Joska2, Ryan R Lion3, Melissa H Watt3, Warren Burnhams4, Adam W Carrico5, Christina S Meade6,7. 1. Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa. 2. HIV Mental Health Research Unit, Division of Neuropsychiatry, University of Cape Town, Cape Town, South Africa. 3. Duke Global Health Institute, Duke University, Durham, NC, USA. 4. Substance Abuse, City Health, Cape Town, South Africa. 5. School of Nursing, University of California, San Francisco, USA. 6. Duke Global Health Institute, Duke University, Durham, NC, USA. christina.meade@duke.edu. 7. Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, USA. christina.meade@duke.edu.
Abstract
INTRODUCTION AND AIMS: Methamphetamine use is highly prevalent in parts of South Africa, and there is concern this will contribute to the country's substantial HIV epidemic. We examined the feasibility of implementing routine HIV testing at a community-based substance abuse treatment centre in Cape Town and determined the HIV sero-prevalence among methamphetamine users seeking treatment at this site. DESIGN AND METHODS: In this cross-sectional study, 293 participants completed measures of demographics, substance use and HIV treatment. HIV sero-prevalence was determined by a rapid finger-prick HIV test, and prior HIV diagnosis was confirmed via clinic records. RESULTS: The majority of participants were male and self-identified as 'Coloured', with a mean age of 28 years. The HIV sero-prevalence was 3.8%. Of the 11 participants who tested HIV positive, four were newly diagnosed. HIV-positive and HIV-negative participants were comparable on demographic and substance use factors. Uptake of HIV testing among all clients at the drug treatment centre increased from <5% prior to study initiation to 89% after study completion. Measures implemented to ensure high rates of HIV testing were regarded as sustainable. DISCUSSION AND CONCLUSIONS: Our study suggests that integrating routine HIV testing into substance abuse treatment is feasible in a community-based health centre. The low HIV prevalence among this sample of treatment-seeking methamphetamine users highlights the potential benefits of supporting expanded efforts to optimise HIV prevention with this young adult population. [Gouse H, Joska JA, Lion RR, Watt MH, Burnhams W, Carrico AW, Meade CS. HIV testing and sero-prevalence among methamphetamine users seeking substance abuse treatment in Cape Town. Drug Alcohol Rev 2016;35:580-583].
INTRODUCTION AND AIMS: Methamphetamine use is highly prevalent in parts of South Africa, and there is concern this will contribute to the country's substantial HIV epidemic. We examined the feasibility of implementing routine HIV testing at a community-based substance abuse treatment centre in Cape Town and determined the HIV sero-prevalence among methamphetamine users seeking treatment at this site. DESIGN AND METHODS: In this cross-sectional study, 293 participants completed measures of demographics, substance use and HIV treatment. HIV sero-prevalence was determined by a rapid finger-prick HIV test, and prior HIV diagnosis was confirmed via clinic records. RESULTS: The majority of participants were male and self-identified as 'Coloured', with a mean age of 28 years. The HIV sero-prevalence was 3.8%. Of the 11 participants who tested HIV positive, four were newly diagnosed. HIV-positive and HIV-negative participants were comparable on demographic and substance use factors. Uptake of HIV testing among all clients at the drug treatment centre increased from <5% prior to study initiation to 89% after study completion. Measures implemented to ensure high rates of HIV testing were regarded as sustainable. DISCUSSION AND CONCLUSIONS: Our study suggests that integrating routine HIV testing into substance abuse treatment is feasible in a community-based health centre. The low HIV prevalence among this sample of treatment-seeking methamphetamine users highlights the potential benefits of supporting expanded efforts to optimise HIV prevention with this young adult population. [Gouse H, Joska JA, Lion RR, Watt MH, Burnhams W, Carrico AW, Meade CS. HIV testing and sero-prevalence among methamphetamine users seeking substance abuse treatment in Cape Town. Drug Alcohol Rev 2016;35:580-583].
Authors: Michael W Plankey; David G Ostrow; Ron Stall; Christopher Cox; Xiuhong Li; James A Peck; Lisa P Jacobson Journal: J Acquir Immune Defic Syndr Date: 2007-05-01 Impact factor: 3.731
Authors: Christina S Meade; Sheri L Towe; Melissa H Watt; Andrea L Hobkirk; Donald Skinner; Bronwyn Myers; Stephen M Kimani; Desiree Pieterse Journal: AIDS Behav Date: 2015-01
Authors: Louisa Degenhardt; Bradley Mathers; Mauro Guarinieri; Samiran Panda; Benjamin Phillips; Steffanie A Strathdee; Mark Tyndall; Lucas Wiessing; Alex Wodak; John Howard Journal: Int J Drug Policy Date: 2010-02-01
Authors: Wendee M Wechsberg; Hendree E Jones; William A Zule; Bronwyn J Myers; Felicia A Browne; Michelle R Kaufman; Winnie Luseno; Alan J Flisher; Charles D H Parry Journal: Am J Drug Alcohol Abuse Date: 2010-07 Impact factor: 3.829
Authors: Lisa R Metsch; Daniel J Feaster; Lauren Gooden; Tim Matheson; Raul N Mandler; Louise Haynes; Susan Tross; Tiffany Kyle; Dianne Gallup; Andrzej S Kosinski; Antoine Douaihy; Bruce R Schackman; Moupali Das; Robert Lindblad; Sarah Erickson; P Todd Korthuis; Steve Martino; James L Sorensen; José Szapocznik; Rochelle Walensky; Bernard Branson; Grant N Colfax Journal: Am J Public Health Date: 2012-04-19 Impact factor: 9.308
Authors: Tamar Krishnamurti; Kimberly Ling Murtaugh; Lara Van Nunen; Alexander L Davis; Jonathan Ipser; Steven Shoptaw Journal: J Subst Abuse Treat Date: 2020-01-25
Authors: Chukwuemeka N Okafor; Dan J Stein; Lisa Dannatt; Jonathan Ipser; Lara J van Nunen; Marilyn T Lake; Tamar Krishnamurti; Edythe D London; Steve Shoptaw Journal: Drug Alcohol Rev Date: 2019-12-21
Authors: Shakiera T Causey; Sheri L Towe; Jeremiah Hartsock; Yunan Xu; Christina S Meade Journal: Subst Use Misuse Date: 2021-05-25 Impact factor: 2.362